GSK's mRNA Flu Vaccine Advances to Late-Stage Clinical Development After Positive Trial Results
By Christian Moess Laursen
GSK said its would move its seasonal mRNA flu vaccine to late-stage clinical development after positive Phase 2 trial results.
The British pharma giant said Thursday that the trial studied a range of mRNA formulations in older and younger adults to evaluate vaccine candidates that could improve immune responses against influenza type A and B.
There are four types of influenza viruses, with A and B being the two types that cause most human illness and that are responsible for flu seasons each year.
In both younger and older adults, pre-defined success criteria were met in the Phase 2 trial, GSK said.
The mRNA seasonal influenza vaccine program would now progress into late-stage clinical development, or Phase 3, GSK said.
"Ultimately, our goal is to develop a new best-in-class vaccine to bring greater protection to people through the influenza season," chief scientific officer, Tony Wood, said.
In July, GSK signed a new licensing agreement with CureVac to assume full control of developing and manufacturing influenza and Covid-19 candidate vaccines.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
September 12, 2024 02:50 ET (06:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
-
Real Estate: Performance Continues to Be Driven by Interest-Rate Movements
-
Financial Services: Sector Doing Well Heading Into Rate-Cutting Cycle
-
Energy: OPEC Faces Hard Supply Decision in Latter Half of 2024
-
This Cheap Stock Is Still a Buy Even After 50% Rally